The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
112
Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
CH d'AIX
Aix-en-Provence, France
CHU de DIJON
Dijon, France
CHD Vendée
La Roche-sur-Yon, France
Ch Le Mans
Le Mans, France
CH de MACON
Mâcon, France
Autoimmune disease flare
Increase in the activity of the pre-existing autoimmune disease as assessed by the treating physician
Time frame: through study completion, an average of 1 year
Other immune/inflammatory complications
Development of a new immune/inflammatory condition after the start of the therapy
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.